ADLAI NORTYE LTD-ADR (ANL) Stock Price, Quote, News and Overview
NASDAQ:ANL - Nasdaq - US00704R1095 - ADR - Currency: USD
ANL Quote, Performance and Key Statistics
NASDAQ:ANL (3/7/2025, 8:05:00 PM)
2.3115
+0.09 (+4.12%)
The current stock price of ANL is 2.3115 USD. In the past month the price increased by 11.13%. In the past year, price decreased by -69.78%.
ANL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ANL
Company Profile
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. The firm is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
Company Info
ADLAI NORTYE LTD-ADR
c/o PO Box 309, Ugland House
George Town KY
Employees: 127
Company Website: http://www.adlainortye.com/
Phone: 18482307430
ADLAI NORTYE LTD-ADR / ANL FAQ
What is the stock price of ADLAI NORTYE LTD-ADR today?
The current stock price of ANL is 2.3115 USD. The price increased by 4.12% in the last trading session.
What is the ticker symbol for ADLAI NORTYE LTD-ADR stock?
The exchange symbol of ADLAI NORTYE LTD-ADR is ANL and it is listed on the Nasdaq exchange.
On which exchange is ANL stock listed?
ANL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADLAI NORTYE LTD-ADR stock?
5 analysts have analysed ANL and the average price target is 9.18 USD. This implies a price increase of 297.14% is expected in the next year compared to the current price of 2.3115. Check the ADLAI NORTYE LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADLAI NORTYE LTD-ADR worth?
ADLAI NORTYE LTD-ADR (ANL) has a market capitalization of 85.30M USD. This makes ANL a Micro Cap stock.
How many employees does ADLAI NORTYE LTD-ADR have?
ADLAI NORTYE LTD-ADR (ANL) currently has 127 employees.
What are the support and resistance levels for ADLAI NORTYE LTD-ADR (ANL) stock?
ADLAI NORTYE LTD-ADR (ANL) has a support level at 2.08 and a resistance level at 2.32. Check the full technical report for a detailed analysis of ANL support and resistance levels.
Is ADLAI NORTYE LTD-ADR (ANL) expected to grow?
The Revenue of ADLAI NORTYE LTD-ADR (ANL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ANL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADLAI NORTYE LTD-ADR (ANL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANL, evaluating the profitability, health, valuation and growth aspects
- ADLAI NORTYE LTD-ADR (ANL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADLAI NORTYE LTD-ADR (ANL) Sales and EPS estimates to see what analysts future expectations are.
- ADLAI NORTYE LTD-ADR (ANL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADLAI NORTYE LTD-ADR (ANL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADLAI NORTYE LTD-ADR (ANL) Stock Chart to make your own analysis
- ADLAI NORTYE LTD-ADR (ANL) Latest news and press-releases to stay up to date.
Does ADLAI NORTYE LTD-ADR (ANL) stock pay dividends?
ANL does not pay a dividend.
What is the Price/Earnings (PE) ratio of ADLAI NORTYE LTD-ADR (ANL)?
ADLAI NORTYE LTD-ADR (ANL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.14).
What is the Short Interest ratio of ADLAI NORTYE LTD-ADR (ANL) stock?
The outstanding short interest for ADLAI NORTYE LTD-ADR (ANL) is 0.01% of its float. Check the ownership tab for more information on the ANL short interest.
ANL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ANL. When comparing the yearly performance of all stocks, ANL is a bad performer in the overall market: 87.22% of all stocks are doing better.
ANL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ANL. Both the profitability and financial health of ANL have multiple concerns.
ANL Financial Highlights
Over the last trailing twelve months ANL reported a non-GAAP Earnings per Share(EPS) of -5.14. The EPS decreased by -365.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.39% | ||
| ROE | -196.51% | ||
| Debt/Equity | 0.73 |
ANL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ANL. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 69.66% and a revenue growth -100% for ANL